Garisto Juan, Nayan Madhur, Fadaak Kamel, Li Kathy, Pandya Advait, Leao Ricardo, Chung Peter, Shridar Srikala S, Helou Joelle, Kulkarni Girish S
University of Toronto, Toronto, ON, Canada.
Can Urol Assoc J. 2021 Jun;15(6):187-191. doi: 10.5489/cuaj.6762.
Squamous cell carcinoma (SCC) of the penis is a rare disease comprising 1% of all male cancer. Options for the management of cT1-T2 cN0 penile SCC include partial penectomy (PP), considered the standard, and brachytherapy (BT), which offers acceptable local disease control and organ preservation. The purpose of our study was to assess and describe the oncological outcome for both treatments in a tertiary care center.
We performed a contemporary retrospective study of patients with early-stage penile cancer treated surgically or by BT at a tertiary center between 2000 and 2016. Demographic, management, and followup data were obtained from an institutional database. Descriptive statistics and survival analysis using Kaplan-Meier plots were calculated. Local and regional recurrences were compared in both groups (BT vs. PP).
A total of 51 patients with cT1-T2N0 penile SCC treated with BT (35) and PP (16) were analyzed. Median followup was 37.1 (13.9-68) and 25.4 months (18-52.3) for the BT and PP groups, respectively. Recurrence developed in seven (20%) patients treated with BT. Median time to recurrence was 35.2 months (range 2.9-95.8). No recurrences were reported in patients treated with PP. Forty-four (86.2%) patients were alive with no evidence of disease at the last followup. Overall survival was 62.7%. Complications after primary tumor treatment were urethral stenosis (15.7%), penile necrosis (7.8%), and local infection (2%).
PP provides acceptable local control with organ preservation in early-stage penile SCC. BT was able to offer organ preservation in 69% of men. Future prospective studies are needed to compare other organ-conserving treatment modalities with PP.
阴茎鳞状细胞癌(SCC)是一种罕见疾病,占所有男性癌症的1%。cT1-T2 cN0期阴茎SCC的治疗选择包括部分阴茎切除术(PP),被视为标准治疗方法,以及近距离放射治疗(BT),其能提供可接受的局部疾病控制并保留器官。我们研究的目的是评估并描述在三级医疗中心这两种治疗方法的肿瘤学结果。
我们对2000年至2016年期间在三级中心接受手术或BT治疗的早期阴茎癌患者进行了一项当代回顾性研究。人口统计学、治疗和随访数据来自机构数据库。计算了描述性统计数据并使用Kaplan-Meier曲线进行生存分析。比较了两组(BT与PP)的局部和区域复发情况。
共分析了51例接受BT(35例)和PP(16例)治疗的cT1-T2N0期阴茎SCC患者。BT组和PP组的中位随访时间分别为37.1(13.9 - 68)个月和25.4个月(18 - 52.3)。接受BT治疗的7例(20%)患者出现复发。复发的中位时间为35.2个月(范围2.9 - 95.8)。接受PP治疗的患者未报告复发。44例(86.2%)患者在最后一次随访时存活且无疾病证据。总生存率为62.7%。原发性肿瘤治疗后的并发症包括尿道狭窄(15.7%)、阴茎坏死(7.8%)和局部感染(2%)。
PP在早期阴茎SCC中能提供可接受的局部控制并保留器官。BT能够为69%的男性保留器官。未来需要进行前瞻性研究,以将其他保留器官的治疗方式与PP进行比较。